What’s Ahead for Omeros Corporation (NASDAQ:OMER) After Less Shorted Shares?

October 11, 2018 - By Vivian Park

Omeros Corporation (NASDAQ:OMER) Logo

Investors sentiment increased to 1.38 in 2018 Q2. Its up 0.34, from 1.04 in 2018Q1. It increased, as 13 investors sold Omeros Corporation shares while 21 reduced holdings. 20 funds opened positions while 27 raised stakes. 21.45 million shares or 5.18% more from 20.39 million shares in 2018Q1 were reported.
Dekabank Deutsche Girozentrale owns 19,200 shares. California State Teachers Retirement System invested in 70,129 shares or 0% of the stock. Goldman Sachs Grp Inc stated it has 0% in Omeros Corporation (NASDAQ:OMER). Schwab Charles Invest Mngmt invested in 239,828 shares or 0% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% in Omeros Corporation (NASDAQ:OMER). Commercial Bank Of Ny Mellon owns 0% invested in Omeros Corporation (NASDAQ:OMER) for 214,633 shares. State Board Of Administration Of Florida Retirement System reported 31,737 shares stake. Stifel has 0.03% invested in Omeros Corporation (NASDAQ:OMER) for 465,411 shares. The Ohio-based Meeder Asset Mngmt Incorporated has invested 0% in Omeros Corporation (NASDAQ:OMER). Gradient Investments Limited Liability Company accumulated 503 shares. California Employees Retirement Sys owns 49,900 shares. Bancshares Of Montreal Can stated it has 41,683 shares or 0% of all its holdings. State Common Retirement Fund holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 49,400 shares. Manufacturers Life Insur The holds 0% or 55,808 shares in its portfolio. Piedmont Inv Ltd Limited Liability Company has 0% invested in Omeros Corporation (NASDAQ:OMER) for 796 shares.

Since May 14, 2018, it had 0 insider buys, and 4 sales for $2.59 million activity. Kelbon Marcia S. sold $91,886 worth of Omeros Corporation (NASDAQ:OMER) on Thursday, July 12.

The stock of Omeros Corporation (NASDAQ:OMER) registered a decrease of 4.83% in short interest. OMER’s total short interest was 8.40M shares in October as published by FINRA. Its down 4.83% from 8.83 million shares, reported previously. With 567,300 shares average volume, it will take short sellers 15 days to cover their OMER’s short positions.

The stock increased 1.90% or $0.26 during the last trading session, reaching $13.97. About 251,834 shares traded. Omeros Corporation (NASDAQ:OMER) has risen 28.58% since October 11, 2017 and is uptrending. It has outperformed by 12.96% the S&P500.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $678.38 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 3 analysts covering Omeros Corp (NASDAQ:OMER), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Omeros Corp had 6 analyst reports since April 19, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Friday, August 10 by Maxim Group. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) on Friday, May 11 with “Buy” rating. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, May 3. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) on Thursday, April 19 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $3400 target in Friday, May 25 report. The firm has “Hold” rating given on Wednesday, May 16 by Wedbush.

More notable recent Omeros Corporation (NASDAQ:OMER) news were published by: Streetinsider.com which released: “Pre-Open Movers 10/02: (DTEA) (OMER) (CLVS) Higher; (SFIX) (NBEV) (VNE) Lower (more…)” on October 02, 2018, also Seekingalpha.com with their article: “Omeros: Substantial Unlocked Value In The GPCR Franchise” published on September 17, 2018, Benzinga.com published: “Omeros Shares Fall Over 40% On Renal Disease Trial Results” on October 01, 2018. More interesting news about Omeros Corporation (NASDAQ:OMER) were released by: Businesswire.com and their article: “Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA” published on October 01, 2018 as well as Fool.com‘s news article titled: “Why Omeros Corporation Stock Is Bouncing Back Today” with publication date: October 02, 2018.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>